These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24562046)

  • 1. A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients.
    Shida S; Takahashi N; Miura M; Niioka T; Matsumoto M; Hagihara M; Kobayashi T; Abumiya M; Kameoka Y; Fujishima N; Tagawa H; Hirokawa M; Sawada K
    Ther Drug Monit; 2014 Aug; 36(4):505-9. PubMed ID: 24562046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients.
    Miura M; Satoh S; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Suzuki T
    Ther Drug Monit; 2008 Feb; 30(1):52-9. PubMed ID: 18223463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma.
    Kobayashi T; Miura M; Abumiya M; Akamine Y; Ito F; Takahashi N
    Med Oncol; 2019 May; 36(6):55. PubMed ID: 31089832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of lenalidomide in multiple myeloma patients.
    Guglieri-López B; Pérez-Pitarch A; Moes DJ; Porta-Oltra B; Climente-Martí M; Guchelaar HJ; Merino-Sanjuán M
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):189-200. PubMed ID: 28039509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.
    Dao K; Lu Y; Peer CJ; Figg WD; Stadelmann R; Burnier M; Buclin T; Kissling S
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):215-218. PubMed ID: 27988790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma.
    Kamikawa R; Ikawa K; Morikawa N; Asaoku H; Iwato K; Sasaki A
    Biol Pharm Bull; 2006 Nov; 29(11):2331-4. PubMed ID: 17077542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.
    Chen N; Zhou S; Palmisano M
    Clin Pharmacokinet; 2017 Feb; 56(2):139-152. PubMed ID: 27351179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide.
    Kobayashi T; Miura M; Niioka T; Abumiya M; Ito F; Kobayashi I; Ikeda S; Yoshioka T; Kameoka Y; Takahashi N
    Ther Drug Monit; 2018 Jun; 40(3):301-309. PubMed ID: 29494421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
    Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA
    Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
    Kaczmarek I; Bigdeli AK; Vogeser M; Mueller T; Beiras-Fernandez A; Kaczmarek P; Schmoeckel M; Meiser B; Reichart B; Ueberfuhr P
    Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
    Bridoux F; Chen N; Moreau S; Arnulf B; Moumas E; Abraham J; Desport E; Jaccard A; Fermand JP
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):173-82. PubMed ID: 27286995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
    Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
    Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis.
    Kobayashi T; Niioka T; Miura M; Takahashi N
    Ann Hematol; 2016 Dec; 95(12):2087-2088. PubMed ID: 27595758
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclosporine A area-under-time-concentration-curve in rheumatologic patients after the first dose. Which of the sparse sampling strategies will predict the best?
    Koristkova B; Grundmann M; Suchy D; Perinova I; Brozmanova H; Mayer O
    Int J Clin Pharmacol Ther; 2011 May; 49(5):311-20. PubMed ID: 21543034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.
    Muscal JA; Sun Y; Nuchtern JG; Dauser RC; McGuffey LH; Gibson BW; Berg SL
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):943-7. PubMed ID: 22109830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Wide Linearity Range Method for the Determination of Lenalidomide in Plasma by High-Performance Liquid Chromatography: Application to Pharmacokinetic Studies.
    Guglieri-López B; Pérez-Pitarch A; Martinez-Gómez MA; Porta-Oltra B; Climente-Martí M; Merino-Sanjuán M
    J Lab Autom; 2016 Dec; 21(6):806-810. PubMed ID: 26956578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
    Dasanu CA; Bockorny B; Alexandrescu DT
    J Oncol Pharm Pract; 2015 Dec; 21(6):471-3. PubMed ID: 24986794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LC-MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients.
    Shu C; Zeng T; Gao S; Xia T; Huang L; Zhang F; Chen W
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():111-119. PubMed ID: 27336703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
    Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
    Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.